NRIX
Nurix Therapeutics, Inc.Healthcare·Biotechnology
$17.76
$1.5B market cap
Revenue
$19.8M
Free Cash Flow
$-145.9M
Rev Growth
+0.0%
FCF Margin
-735.9%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an o
2-Year Price History
$17.50+11.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 6.3 | -92.5 | -92.5 | -87.2 | -71.9 | -73.0 | -1.0 | 540.7 | 58.7 | 110.1 | -213.7% | -- | -- |
| Act | 2025-Q4 | 13.6 | -69.0 | -83.1 | -78.2 | -67.8 | -73.0 | -5.1 | 592.9 | 55.7 | 95.1 | -144.0% | -- | -- |
Valuation & Metrics
Market Stats
Price$17.76
Market Cap$1.5B
Enterprise Value$1.1B
P/S Ratio77.6x
P/FCF--
EV/FCF--
FCF Margin (TTM)-735.9%
FCF Yield-9.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$19.8M
Net Income$-165.4M
Free Cash Flow$-145.9M
Revenue Growth (YoY)+0.0%
EBITDA Margin-814.2%
Net Margin-834.1%
FCF Margin-735.9%
CapEx % of Revenue31.1%
SBC % of Revenue0.0%
ROIC-178.8%
WC Change % Rev-16.8%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares19.2M
Days to Cover24.3
Change (vs Prior)+0.0%
Need at least 2 settlement dates for chart
Employees
Headcount286
Revenue / Employee$69,332
Gross Profit / Employee$-241,045
Cash Runway
44.5months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
94.2%(+42.5% YoY)
174 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
25.0%(+10.7% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.0% YoY)
9 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| BlackRock, Inc.Passive | $138M | $21.21 | +$782K | +$14.6M | -0.2% | $5.69T |
| Redmile Group, LLC | $120M | $17.39 | −$5.6M | +$57.1M | -5.6% | $1.51B |
| Vestal Point Capital, LP | $101M | $14.28 | +$28.1M | +$83.3M | -0.1% | $3.58B |
| Deep Track Capital, LP | $98.4M | $13.68 | −$10.7M | +$13.1M | -1.1% | $4.85B |
| FMR LLC | $85.9M | $18.25 | +$20.3M | −$74.3M | -0.0% | $1.89T |
| STATE STREET CORPPassive | $79.7M | $15.27 | +$24.5M | +$35.3M | -0.2% | $2.89T |
| MORGAN STANLEY | $76.4M | $13.99 | +$789K | +$53.7M | -0.3% | $1.65T |
| BAKER BROS. ADVISORS LP | $72.2M | $14.89 | +$0 | +$12.0M | -0.4% | $16.13B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $68.6M | $15.50 | +$68.6M | +$68.6M | — | $4.04T |
| GENERAL ATLANTIC, L.P. | $63.6M | $18.97 | −$12.3M | +$63.6M | -4.6% | $2.15B |
| PERCEPTIVE ADVISORS LLC | $57.5M | $16.37 | +$2.4M | +$52.9M | -1.3% | $5.05B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $51.0M | $19.24 | +$649K | +$5.8M | -0.2% | $864.93B |
| Pictet Asset Management Holding SA | $42.3M | $16.58 | −$11.5M | +$15.1M | -1.1% | $94.52B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $39.1M | $16.09 | +$2.1M | +$12.3M | +2.3% | $1.61T |
| Rubric Capital Management LP | $38.3M | $18.97 | +$0 | +$38.3M | +0.4% | $8.16B |
| DEUTSCHE BANK AG\ | $35.6M | $13.71 | −$3.0M | +$29.7M | -0.3% | $302.17B |
| Commodore Capital LP | $35.3M | $18.63 | +$0 | −$26.4M | +0.1% | $1.73B |
| BRAIDWELL LP | $27.1M | $18.97 | −$6.7M | +$27.1M | -1.8% | $2.63B |
| Trails Edge Capital Partners, LP | $27.0M | $18.97 | +$0 | +$27.0M | +14.9% | $425M |
| ARK Investment Management LLC | $26.7M | $11.32 | +$1.8M | +$2.0M | -1.7% | $12.86B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.70%
avg per quarter
Holders (ex-self)
-0.63%
excl. this stock
Buyers (this Q)
-0.03%
71 buyers · $0.22B in
Sellers (this Q)
-1.35%
52 sellers · $0.29B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-1.6%
how holders react when this stock falls
On quiet Qs
+21.5%
−10% to +10% baseline
On rallies (+10%+)
+1.2%
how they react when this stock rises
Holders' portfolio flow this Q
+4.3%
inflows — adds are organic
Sellers' portfolio flow this Q
-1.4%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.8%
Holder mid (any stock)
-3.1%
Holder rally (any stock)
-5.9%
Biggest decreases this quarter
GENERAL ATLANTIC, L.P.−$12.3Mα-4.6Kynam Capital Management, LP−$12.0Mα+0.5Pictet Asset Management Holding SA−$11.5Mα-1.1Deep Track Capital, LP−$10.7Mα-1.1Logos Global Management LPexited−$9.5MBRAIDWELL LP−$6.7Mα-1.8Redmile Group, LLC−$5.6Mα-5.6Ensign Peak Advisors, Incexited−$4.4MT. Rowe Price Investment Management, Inc.exited−$3.3MDEUTSCHE BANK AG\−$3.0Mα-0.3
New buyers this quarter
Top-5 holders · 29.9%
BlackRock, Inc.--
Redmile Group, LLC--
Vestal Point Capital, LP--
Deep Track Capital, LP--
FMR LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC5.5MRedmile Group, LLC7.7MPRICE T ROWE ASSOCIATES INC /MD/3.3MDeep Track Capital, LP6.3MVestal Point Capital, LP6.5MGENERAL ATLANTIC, L.P.4.1MMORGAN STANLEY4.9MTRV GP III, LLC—BAKER BROS. ADVISORS LP4.7MWELLINGTON MANAGEMENT GROUP LLP321K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$28.005770.0%
Last Year (19 analysts)$28.956300.0%
Current Price$17.76
Analyst Ratings
17
Buy: 17Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$2.52M
23 txns · 3 insiders · 160,067 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-05 | SELL | van Houte Hans | officer: Chief Financial Officer | 14,055 | $16.60 | $233K | $624K |
| 2026-05-04 | SELL | Ring Christine | officer: Chief Legal Officer | 8,148 | $16.96 | $138K | $310K |
| 2026-05-01 | SELL | Ring Christine | officer: Chief Legal Officer | 5,394 | $16.76 | $90K | $443K |
| 2026-04-30 | SELL | Hansen Gwenn | officer: Chief Scientific Officer | 3,214 | $16.65 | $53K | $2.00M |
| 2026-04-30 | SELL | Ring Christine | officer: Chief Legal Officer | 3,214 | $16.65 | $53K | $530K |
| 2026-04-30 | SELL | van Houte Hans | officer: Chief Financial Officer | 2,388 | $16.65 | $40K | $860K |
| 2026-04-02 | SELL | Ring Christine | officer: Chief Legal Officer | 8,148 | $15.24 | $124K | $403K |
| 2026-03-02 | SELL | Ring Christine | officer: Chief Legal Officer | 8,148 | $15.44 | $126K | $534K |
| 2026-02-09 | SELL | Ring Christine | officer: Chief Legal Officer | 14,261 | $16.66 | $238K | $712K |
| 2026-01-30 | SELL | Ring Christine | officer: Chief Legal Officer | 4,421 | $16.60 | $73K | $946K |
| 2026-01-30 | SELL | van Houte Hans | officer: Chief Financial Officer | 3,661 | $16.60 | $61K | $754K |
| 2026-01-30 | SELL | Hansen Gwenn | officer: Chief Scientific Officer | 4,895 | $16.60 | $81K | $1.39M |
| 2026-01-20 | SELL | Ring Christine | officer: Chief Legal Officer | 3,760 | $18.42 | $69K | $938K |
| 2025-12-18 | SELL | Ring Christine | officer: Chief Legal Officer | 3,760 | $17.90 | $67K | $911K |
| 2025-11-24 | SELL | Ring Christine | officer: Chief Legal Officer | 37,600 | $17.07 | $642K | $869K |
| 2025-11-03 | SELL | van Houte Hans | officer: Chief Financial Officer | 6,284 | $12.56 | $79K | $472K |
| 2025-10-30 | SELL | Hansen Gwenn | officer: Chief Scientific Officer | 4,087 | $12.80 | $52K | $982K |
| 2025-10-30 | SELL | Ring Christine | officer: Chief Legal Officer | 3,644 | $12.80 | $47K | $651K |
| 2025-10-30 | SELL | van Houte Hans | officer: Chief Financial Officer | 3,130 | $12.80 | $40K | $561K |
| 2025-08-01 | SELL | van Houte Hans | officer: Chief Financial Officer | 5,402 | $11.03 | $60K | $392K |
Order Flow (FINRA, ~3w lag)
8.0%retail-2.7pp
31.5%dark+5.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Nurix Therapeutics: An AI-Powered Pipeline Floating on a Sea of Relentless Shareholder Dilution
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
6/10
Earnings Overstated
5/10
Hidden Liabilities
4/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
8/10